Navigation Links
Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report second quarter 2013 operational results after closing of the NASDAQ Global Market on August 13, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update at 5 p.m. EDT (2 p.m. PDT), August 13, 2013.

The call will be webcast live and may be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify to the operator that you would like to join the "Ambit Second Quarter 2013 Operating Results Call, conference ID 35424048."  A teleconference replay will be available through Monday, August 19, 2013.  Interested parties can access the replay by dialing 888-843-7419, or 630-652-3042 internationally, and entering the conference number 35424048.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit Biosciences website at  An online replay will be available following the initial broadcast until Friday, September 13, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.


Alan Fuhrman (Investors)
Ambit Biosciences
(858) 334-2125

Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
2. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
3. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
6. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
9. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
10. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
11. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... recent 2015 American Dental Association meeting in Washington D.C. revolved around the fact that ... patient’s overall health. The talk stressed the link between periodontal disease (more commonly referred ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the health care in America. As people age, more care is needed, especially ... are rising, and medical professionals are being overworked. The forgotten part of this ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... toilets were," said an inventor from Hillside, N.J. "Many people catch diseases simply ... so that individuals will always be protected from germs." , He developed the ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):